Summary of Significant Accounting Policies (Details)			12 Months Ended
	Feb. 08, 2021 USD ($) $ / shares shares	Jun. 07, 2019 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) Segment shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) shares	Sep. 28, 2021 $ / shares
Summary Of Significant Accounting Policies [Line Items]
Impairment of tangible long-lived assets			$ 0	$ 0	$ 0
Cash and cash equivalents			$ 51,772,000	54,967,000	87,608,000
Number of reportable segments | Segment			1
Goodwill impairment charge			$ 0	0	0
Goodwill recognized in asset acquisition			9,202,000	9,202,000
Indefinite-lived intangible assets impairment charges			0	0	0
Replacement implants and revision surgery financial assistance under limited warranty program			2,505,000	$ 1,934,000	$ 1,397,000
Series of Individually Immaterial Asset Acquisitions
Summary Of Significant Accounting Policies [Line Items]
Goodwill recognized in asset acquisition			$ 0
Silicone Gel Breast Implant Surgeries Occurring Prior to May 1, 2018
Summary Of Significant Accounting Policies [Line Items]
Period to claim financial assistance under limited warranty program			10 years
Silicone Gel Breast Implants Occurring on or after May 1, 2018
Summary Of Significant Accounting Policies [Line Items]
Period to claim financial assistance under limited warranty program			20 years
Common stock
Summary Of Significant Accounting Policies [Line Items]
Proceeds from follow-on offering, net of costs (in shares) | shares			6,222,222	37,000	20,000,000
Underwritten Follow-On Offering | Common stock
Summary Of Significant Accounting Policies [Line Items]
Proceeds from follow-on offering, net of costs (in shares) | shares	5,410,628	17,391,305
Public offering price (in dollars per share) | $ / shares	$ 6.75	$ 5.75
Additional shares granted to underwriters | shares	811,594	2,608,695
Proceeds from the issuance of common stock, net of underwriting discounts, commissions and offering expenses	$ 39,200,000	$ 107,700,000
Payment of underwriting discounts and commissions and offering expenses	2,500,000	6,900,000
Offering expenses	$ 300,000	$ 400,000
Maximum | Silicone Gel Breast Implant Surgeries Occurring Prior to May 1, 2018
Summary Of Significant Accounting Policies [Line Items]
Replacement implants and revision surgery financial assistance under limited warranty program			$ 3,600
Maximum | Silicone Gel Breast Implants Occurring on or after May 1, 2018
Summary Of Significant Accounting Policies [Line Items]
Replacement implants and revision surgery financial assistance under limited warranty program			$ 5,000
Deerfield Facility Agreement | Maximum
Summary Of Significant Accounting Policies [Line Items]
Public offering price (in dollars per share) | $ / shares						$ 1.50
Deerfield Facility Agreement | Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Public offering price (in dollars per share) | $ / shares						$ 30.00